TaiMed Biologics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TaiMed Biologics Inc. - overview
Established
2007
Location
Taipei, -, Taiwan - China
Primary Industry
Biotechnology
About
Established in 2007 and based in Taipei, China, TaiMed Biologics Inc. operates as a biologics developer that focuses on the clinical development of biotherapeutics. It has an approximately 60,000 square feet of facility. The company is headquartered in Taipei, and has a branch in Hsinchu and a subsidiary in the USA.
In March 2010, it raised USD 22 million in Series B financing from YFY Biotech Management Company. In March 2018, its product TMB-355 was approved by the US FDA as a new protein drug. Dayi He, the co-founder of the company, is an academician of Academia Sinica and director and CEO of the AIDS Research Center. The company cooperates with tanvex, WuXi AppTec and Samsung Biologics, etc.
The company is engages in the research and development of biotherapeutics. Its products include Trogarzo® intravenous injection, Trogarzo® intravenous bolus injection, Trogarzo® intramuscular injection, TMB-365 and TMB-380 double antibody compound combination. The company also provides biological agents commissioned development and manufacturing (CDMO) services.
Current Investors
National Development Fund of the Executive Yuan, YFY Biotech Management
Primary Industry
Biotechnology
Sub Industries
BPO Services, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.taimedbiologics.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.